Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Vismodegib.

Rudin CM.

Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7.

2.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
3.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
4.

Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

Lyseng-Williamson KA, Keating GM.

Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.

PMID:
23329081
5.

Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.

Dubey AK, Dubey S, Handu SS, Qazi MA.

J Postgrad Med. 2013 Jan-Mar;59(1):48-50. Review.

6.

Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.

Sobanko JF, Okman J, Miller C.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s154-5. Review.

PMID:
24085062
7.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.

N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.

8.

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N.

Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. Review.

PMID:
25690490
9.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Keating GM.

Drugs. 2012 Jul 30;72(11):1535-41. doi: 10.2165/11209590-000000000-00000. Review.

PMID:
22788238
10.

Vismodegib (Erivedge) for basal cell carcinoma.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4. No abstract available.

PMID:
22777303
11.

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.

Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, Kufrin D, Palmby T, Dong Z, Russell AM, Miksinski S, Keegan P, Pazdur R.

Clin Cancer Res. 2013 May 1;19(9):2289-93. doi: 10.1158/1078-0432.CCR-12-1956. Epub 2013 Mar 20.

12.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
13.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
14.

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Dessinioti C, Plaka M, Stratigos AJ.

Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.

PMID:
24941979
15.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
16.

Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.

Bayers S, Kapp DL, Beer KR, Slavin B.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s147-50. Review.

PMID:
24085060
17.

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.

18.

Vismodegib: a promising drug in the treatment of basal cell carcinomas.

Dirix L, Rutten A.

Future Oncol. 2012 Aug;8(8):915-28. doi: 10.2217/fon.12.82.

PMID:
22894666
19.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ.

J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.

20.

Vismodegib.

Dlugosz A, Agrawal S, Kirkpatrick P.

Nat Rev Drug Discov. 2012 Jun 1;11(6):437-8. doi: 10.1038/nrd3753. No abstract available.

Supplemental Content

Support Center